Nanosonics share price slides lower on business update

Nanosonics shares are falling on Wednesday. Here's why…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Nanosonics share price is in the red on Wednesday
  • This follows the release of a business update
  • Nanosonics revealed that its direct sales model transition in North America is going well

The Nanosonics Ltd (ASX: NAN) share price is dropping on Wednesday.

In morning trade, the infection prevention company's shares are down 1.5% to $3.74.

young female doctor with digital tablet looking confused.

Image source: Getty Images

Why is the Nanosonics share price falling?

The weakness in the Nanosonics share price on Wednesday has been driven by the release of a business update.

This update was in relation to the company's direct sales model transition in North America which was announced in February.

According to the release, the direct sales model transition is progressing well with the transfer of GE customers currently in progress and a significant number of accounts already set up by Nanosonics.

The release notes that GE has been supporting Nanosonics with the transition by communicating with all of their trophon customers about the new arrangements being implemented for the ongoing provision of trophon products.

Furthermore, the relevant GE customer data has been supplied to Nanosonics and the company has communicated with all these customers to set up direct trading accounts. A significant number of these accounts are now in place. Management expects that the transition will be completed for the majority of customers by 30 June 2022.

Also supporting the transition will be a number of former GE High Level Disinfection team members that have joined Nanosonics. These include the previous Head of the GE High Level Disinfection team, a GE operations lead who was responsible for the supply and logistics of trophon products to all GE customers, and a number of sales managers.

Trading update

During the third quarter, Nanosonics' global installed base grew to 28,900. This is up a modest 2.6% from 28,160 units at the end of December. It could be this subdued growth that is weighing on the Nanosonics share price today.

Nevertheless, management revealed that it expects its full-year revenue to be in line with current market consensus estimates.

Furthermore, Nanosonics' Chief Executive Officer and President, Michael Kavanagh, believes the transition will benefit the company. He commented:

The continued transition to a more direct sales channel model in North America brings many benefits to Nanosonics and its customers. Our North American team can now manage the overall growth strategy associated with new installed base, upgrade adoption and consumables usage. This deeper relationship with our North American customers together with our corresponding infrastructure expansion also supports planned product expansion beyond trophon.

We are very pleased with the ongoing progress being made with the transition to the updated sales model. Our North American team and the GE healthcare ultrasound team continue to collaborate well ensuring the current and future infection prevention needs of all customers and their patients are fully met.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics Limited. The Motley Fool Australia has positions in and has recommended Nanosonics Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Sigma Healthcare vs Sonic Healthcare: Which ASX healthcare share wins?

I compare Sigma Healthcare and Sonic Healthcare to reveal which ASX healthcare share I think is the better buy right…

Read more »

A man surrounded by huge piles of paper looks through a magnifying glass at his computer screen.
Opinions

CSL shares are back near $180. Here's the level I'm watching

CSL shares are nearing a key technical level after a strong rebound.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best?

How do Neuren Pharmaceuticals and Telix Pharmaceuticals stack up? Here’s my verdict on which ASX healthcare stock looks more compelling…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Why are Telix Pharmaceuticals shares on the slide today?

Big merger news isn't exciting investors just yet.

Read more »

two hands wearing medical gloves make the shape of a heart, indicating the best healthcare shares on the ASX market
Healthcare Shares

Down more than 18% in a month with a 7% yield, are Sonic Healthcare shares too cheap to ignore?

This could be a very healthy opportunity to buy.

Read more »

A man in a business suit jumps over a hurdle with a blue sky background.
Healthcare Shares

Why brokers think CSL shares could be on track for $200

CSL needs to tick a lot of boxes, before it can clear the $200 hurdle.

Read more »

Two scientists looking at a tablet.
Healthcare Shares

Telix Pharmaceuticals: ITM merger builds a sector leader

Telix Pharmaceuticals share price is in focus after announcing a transformative merger with ITM, set to expand its radiopharmaceutical pipeline.

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

1 ASX dividend stock down 49% I'd buy right now

I think this business is now very appealing.

Read more »